ReviewCurrent psychiatry reports2015
D-cycloserine augmentation of cognitive behavioral therapy for anxiety disorders: an update.
Review in Current psychiatry reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Changes in Dosing and Dose Timing of D-Cycloserine Explain Its Apparent Declining Efficacy for Augmenting Exposure Therapy for Anxiety-related Disorders: An Individual Participant-data Meta-analysis.Journal of anxiety disorders · 2019Pooled it
- Recent Progress in Virtual Reality Exposure Therapy for Phobias: A Systematic Review.Current psychiatry reports · 2017Pooled it
- D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review.The international journal of neuropsychopharmacology · 2016Pooled it
- Augmentation of cognitive and behavioural therapies (CBT) with d-cycloserine for anxiety and related disorders.The Cochrane database of systematic reviews · 2015Pooled it
- Human perceptual learning is delayed by the N-methyl-D-aspartate receptor partial agonist D-cycloserine.Journal of psychopharmacology (Oxford, England) · 2021Trial
- The NMDA receptor partial agonist d-cycloserine does not enhance motor learning.Journal of psychopharmacology (Oxford, England) · 2016Trial
- Enhancing panic and smoking reduction treatment with d-cycloserine: Study protocol for a randomized controlled trial.Contemporary clinical trials · 2016Trial
- Memory persistence: from fundamental mechanisms to translational opportunities.Translational psychiatry · 2024Review
- Molecular mechanisms underlying sex and treatment-dependent differences in an animal model of cue-exposure therapy for cocaine relapse prevention.Frontiers in neuroscience · 2024Article
- Derivatives of (Journal of medicinal chemistry · 2022Article
- Discovery of (Frontiers in chemistry · 2022Article
- Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels.Pharmacological reviews · 2021Review
- Predictors of Treatment Satisfaction Among Adolescents Following an Intensive Cognitive-Behavioral Intervention for Panic Disorder.Child psychiatry and human development · 2021Article
- Is glutamate associated with fear extinction and cognitive behavior therapy outcome in OCD? A pilot study.European archives of psychiatry and clinical neuroscience · 2020Article
- Enhancing prolonged exposure therapy for PTSD among veterans with oxytocin: Design of a multisite randomized controlled trial.Contemporary clinical trials · 2020Article
- Making translation work: Harmonizing cross-species methodology in the behavioural neuroscience of Pavlovian fear conditioning.Neuroscience and biobehavioral reviews · 2019Review
- A precision medicine approach to pharmacological adjuncts to extinction: a call to broaden research.Psychopharmacology · 2019Review
- Acute and long-lasting effects of oxytocin in cortico-limbic circuits: consequences for fear recall and extinction.Psychopharmacology · 2019Review
- Impaired discriminative fear conditioning during later training trials differentiates generalized anxiety disorder, but not panic disorder, from healthy control participants.Comprehensive psychiatry · 2018Article
- From neuroscience to evidence based psychological treatments - The promise and the challenge, ECNP March 2016, Nice, France.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Although cognitive behavioral therapy (CBT) is a generally effective treatment for treating anxiety disorders, there is clearly still room for further improvements. Recent advances in neuroscience of extinction learning led to novel clinical strategies to augment exposure-based treatments with d-cycloserine (DCS), a partial agonist at the glycine recognition site of the glutamatergic N-methyl-D-aspartate receptor. This review provides an update on the current knowledge of DCS as an augmentation strategy of CBT for anxiety disorders. The adequacy of the CBT to be augmented, the dose of DCS, and the timing and duration of augmentation efforts all appear to be important moderating variables. Moreover, there is evidence that DCS may also augment fear memory reconsolidation if the fear level remains high after the exposure. Future studies need to examine whether DCS can augment CBT when administered after exposure in order to develop a tailored administration strategy to maximize its clinical utility.
Indexed as
Identifiers
25413638What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.